21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
10:52 , Jun 7, 2019 |  BC Extra  |  Company News

As Sanofi enters growth phase, Novartis exec Hudson to take the helm

Novartis has lost one executive from each of its Innovative Medicines units in the span of three days, now that Sanofi has named seasoned British sales and marketing executive Paul Hudson as the successor to...
22:37 , May 29, 2019 |  BC Extra  |  Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
23:22 , Apr 9, 2019 |  BC Extra  |  Company News

IFM Tre deal offers glimpse into Novartis' M&A future

Novartis' acquisition of IFM Tre gives a glimpse of its M&A strategy going forward, as the pharma focuses on early stage deals and aims to keep M&A spending at 5% of market cap. Prakash Raman,...
23:50 , Jan 28, 2019 |  BC Extra  |  Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:06 , Dec 20, 2018 |  BC Extra  |  Company News

Barrett joins pharma exodus for biotech

Novartis AG (NYSE:NVS; SIX:NOVN) named its third CEO of oncology in 11 months as Elizabeth Barrett joins the exodus of pharma leaders heading to biotech. Barrett said she will become CEO of an undisclosed U.S.-based...
18:08 , Oct 19, 2018 |  BC Week In Review  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
17:47 , Oct 18, 2018 |  BC Extra  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
18:39 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Altheia lands $11M series A

Altheia Science s.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said. Paolo Rizzardi, Altheia's chairman and...